

Non-Financial Report 2025



„As a family-owned company,
Octapharma maintains a long-term
perspective on everything we do. We see it
as our responsibility to act not only for
today, but for generations to come.“

Tobias Marguerre
Deputy Chairman

General information

- 3 About the Non-Financial Report
- 4 About Octapharma
- 6 Sustainability strategy
- 7 Materiality assessment

Sustainable growth

- 8 Business ethics and integrity

Social responsibility

- 9 Access to treatment
- 10 Patients' quality of life
- 11 Plasma donation
- 12 Employee experience
- 13 Local communities

Environmental stewardship and resilience

- 14 Climate change
- 15 Water
- 17 Use of chemicals
- 17 Resource use

About the Non-Financial Report

This is the Octapharma Group Non-Financial Report relating to the financial year 2025. The Report covers Octapharma Nordic AB (Corporate ID No. 556614-9794) and all entities included in the consolidated accounts for the same period. These entities are specified in the notes of the consolidated accounts. In accordance with the provisions of the Swedish Annual Accounts Act (Chapter 6, paragraph 11), the Report has been prepared separately from the Annual Report. This is the ninth Octapharma Group Non-Financial Report. Its structure and content have been revised to reflect Octapharma's new sustainability strategy and key sustainability topics, determined via a double materiality assessment based on the European Sustainability Reporting Standards (ESRS). Disclosed key performance indicators remain unchanged. In signing the Annual Financial Statement and consolidated accounts of the company, the Board of Directors has approved the Non-Financial Report.



Click links that begin with this symbol to be directed to further information outside of this report.

About Octapharma

Family-owned since being established in 1983, Octapharma is a global healthcare company headquartered in Lachen, Switzerland. Our products are available in 120 countries and reach hundreds of thousands of patients every year.

Octapharma is one of the world's largest human protein product manufacturers. We research, develop and manufacture medicines sourced from human plasma and human cell lines in three therapeutic areas: Haematology, Immunotherapy and Critical Care.



Haematology

Our medicines replace the missing or defective coagulation factor to control or prevent bleeding in people with rare genetic bleeding disorders such as haemophilia A, haemophilia B and von Willebrand disease (VWD). Factor replacement therapy is used to provide patients with the missing clotting factor they need, which enables them to lead normal lives.

Key products: Nuwiq® | octanate® | octanine F® | wilate®



Immunotherapy

We use immunoglobulin G (IgG) contained in human plasma to develop medicines that help the body's immune system fight infections or immune-mediated diseases. IgG immunotherapy is generally used to treat patients with immune deficiencies caused by a genetic defect, by an underlying disease such as cancer or leukaemia, or a drug that suppresses the immune system, or for immunomodulation associated with certain autoimmune diseases.

Key products: cutaquiq® | octagam® | panzyga®



Critical Care

Our therapies are used to quickly restore blood volume, normalise clotting function and prevent shock for patients under intensive care or in emergency medical situations such as sepsis or trauma.


Key products: albuNorm® | atenativ® | octaplasLG® | octaplasLG powder® | fibryga® | octaplex®/balfaxar®



Octapharma places patients at the centre of its work, delivering high quality, plasma-derived and human-based therapies. Across Haematology, Immunotherapy and Critical Care, it treats rare and serious conditions worldwide. Magda's story shows how access to treatment can change daily life and restore independence.



For more patient stories, please visit www.octapharma.com



€ 3.64 bn
revenue

€ 577 m
operating income

11,126
employees

7
R&D centres

5
manufacturing sites

200+
plasma donation centres

Sustainability strategy

Our commitment to sustainability is embedded in our corporate goals, business strategy and governance, as we further integrate it into our operations to ensure long-term growth and value creation. Guided by a long-term vision to provide health solutions that advance human life, with financial discipline and core values as our foundation, we strive to support more patients worldwide while minimising our environmental impact.

Our sustainability strategy has three key elements:



Sustainable growth

We focus on the long term in everything we do. As a family-owned company, Octapharma has always maintained a long-term strategic perspective, based on the belief that the decisions we make today are the foundation for our future success.



Environmental stewardship and resilience

We strive to minimise our environmental footprint. We are committed to reducing our greenhouse gas emissions, water and energy consumption, and use of chemicals while conserving natural resources. We also focus on increasing the resilience of our business to environmental risks.



Social responsibility

People are at the heart of our business. We care for our employees, patients, and plasma donors, and strive to be a responsible corporate citizen in the communities in which we operate.



Materiality assessment

We have conducted a materiality assessment to identify and prioritise our key sustainability topics, understand their strategic relevance, and develop a solid basis for sound sustainability decisions and actions.

The materiality assessment encompassed the entire Octapharma Group, including all subsidiaries, and considered both our own operations and the full upstream and downstream value chain.

To identify potentially material topics, we drew on the sustainability matters listed in Appendix A of ESRS 1, the Ecovadis rating criteria, relevant Global Reporting Initiative (GRI) Standards, and the Sustainability Accounting Standards Board (SASB) materiality map for biotechnology and pharmaceutical companies.

We assessed the impact and financial materiality of these topics during a dedicated one-day workshop with key top management representatives and selected Board Members, resulting in a clear understanding of the most relevant sustainability topics for Octapharma.

Our 10 key sustainability topics are:



Sustainable growth

Business ethics and integrity



Environmental stewardship and resilience

Climate change
Resource use
Use of chemicals
Water




Social responsibility

Access to treatment
Patients' quality of life
Plasma donation
Employee experience
Local communities

Sustainable growth

As a family-owned company, Octapharma has always maintained a long-term strategic perspective, based on the belief that the decisions we make today are the foundation for our future success.



Business ethics and integrity

At Octapharma, integrity is one of our core values. We are committed to operating ethically and being transparent, accountable and responsible in everything we do.

This commitment is supported by clear policies and guidelines, including the Code of Conduct, Integrity Reporting Policy, Compliance Policy, and adherence to the Ethical Interactions in the Pharmaceutical Industry (EIPL) and International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Codes of Conduct.

Our goal is to achieve zero incidents of unethical behaviour among our employees. Employees are encouraged to report any potential misconduct through the Integrity Line, an anonymous whistleblowing system available on our intranet and employee app.

Social responsibility

People are at the heart of our business. We care for our employees, patients and plasma donors, and strive to be a responsible corporate citizen in the communities in which we operate.

Access to treatment

Providing broad and reliable access to high-quality treatments for people around the world is at the heart of our business. This involves ensuring our products are available and affordable while supporting early and accurate diagnosis of diseases.

We collaborate with medical experts to support the early identification and management of conditions such as bleeding disorders, acquired coagulation disorders, autoimmune diseases, and immunodeficiencies.

With Science Hub and OneSource, we provide online training and education platforms that provide engaging content relevant to clinical practice while meeting relevant regulations concerning sharing knowledge with healthcare professionals.

Increasing awareness around Haematology, Immunotherapy and Critical Care conditions is crucial to ensure our products reach the patients who need them. In Haematology, for example, we work to raise awareness about von Willebrand Disease (VWD) – an inherited bleeding disorder that is often misunderstood and underdiagnosed – through the VWDtest.com global online platform, designed to improve its diagnosis.



Science Hub

A global platform for educational resources focusing on Immunotherapy and Critical Care.



OneSource

Platform for healthcare professionals (HCPs) with exclusive content and expert opinions on Haemophilia and VWD.



VWDtest.com

A global platform designed to raise awareness and improve the diagnosis of VWD.

Patients' quality of life

Patients are at the core of our business, and we are committed to making a difference to their lives. Our comprehensive quality management system and drug safety activities enable us to provide safe, effective and reliable treatments to patients.

Our focus is on improving the overall treatment experience, ensuring ease of use, and making our therapies as accessible and practical as possible. Improving outcomes for patients is a key element in the research and development of our products and their application.

We collaborate with leading researchers and patient advocacy groups to better understand the needs of patients, the mechanisms of disease, and how new treatment approaches can improve patients' experiences and the personalisation of care.

We launched flexIG, a digital therapy diary that empowers patients to actively manage subcutaneous immunoglobulin treatments and communicate with their care teams. Instructional videos are available to support home infusion. It was launched in Germany and Italy in 2024, followed by France in 2025, and in Portugal and Lithuania in early 2026, with further country launches planned later this year.

With 8CHECK Octapharma offers a free mutation analysis service for all haemophilia A patients, as well as for people who may be carriers of haemophilia A.



flexIG

flexIG is a smartphone app that is designed specifically to support people who receive ongoing subcutaneous immunoglobulin (IG) replacement therapy.



8CHECK

8CHECK offers free Factor 8 gene variant testing for haemophilia A patients.

„Improving patients' quality of life is not just about product efficacy, but also about their experience with our treatments.“

Olaf Walter
Board Member

Plasma donation

Donated plasma is a critically important resource for plasma-derived therapies used to treat millions of patients worldwide. In an environment where every drop of plasma counts, we strive to ensure the health and safety of donors, the productivity of our plasma donation centres and the quality of the donor experience.

The health and safety of plasma donors are fundamental to our ability to provide life-saving plasma-derived medicines. We ensure the highest standards of donor health, safety and well-being by following specific and highly regulated processes from donation through to the manufacturing of our products.

Facts and figures about plasma donation



Around 200,000 donors visit our US and German plasma donation centres each month.



8 million litres of plasma are collected annually at our plasma donation centres.



It takes **12 months** from plasma donation to patients receiving the medicine.



1,200 plasma donations are needed to treat a patient with haemophilia A for one year.



Plasma donations play a vital role in life-saving therapies, and donors like Charles exemplify the dedication that helps patients around the world. His ongoing commitment highlights the impact of a supportive donation experience.



For more donor stories, please visit www.octapharma.com


Employee experience

We aim to create positive working conditions where innovation can thrive and employees feel supported to deliver their best for patients every day.

Through our training and development programmes, we aim to motivate our employees, boost productivity, and build a skilled, adaptable workforce that will help us grow over the long term.

Our industry is highly regulated, with stringent quality and safety standards. We strive to maintain a safe and accident-free workplace at all our locations. Our production sites have specific targets to prevent or reduce work-related accidents and injuries.

We are committed to fostering an environment where everyone feels they belong and can freely express themselves, while respecting privacy and confidentiality. We want a workplace where every individual feels valued, respected and empowered to contribute to our collective success. We have zero tolerance for any form of discrimination.



Employees by gender	2025		2024		2023	
	Male	Female	Male	Female	Male	Female
Board of Directors Members of parent company Board of Directors by gender	10	0	10	0	10	0
Managers Total number of managers in the Group by gender (excluding Group executive management)	889	784	916	903	736	620
Employees Total number of employees in the Group by gender (excluding Board of Directors, Group executive management and other managers)	3,997	5,446	3,979	5,333	4,233	6,309
Total workforce	4,896	6,230	4,905	6,236	4,979	6,929

Local communities

We aspire to be a good corporate citizen with strong ties to the communities in which we operate. Our overall goal is to build trust through positive relationships with local communities. We seek to minimise the impact of noise or other disruptions on residents, while aiming for minimal disruptions to our own operations.

Examples include:



In Stockholm, regular meetings are held with neighbours and the city council. The site also sponsors a local football club and collaborates with GeBlod – the Swedish national blood donation service – hosting mobile blood donation drives on GeBlod’s “blood bus” at its production site in Stockholm.




The Vienna site encourages employees to support local businesses through partnership programmes. It also organises a festival for residents and sponsors a local football club.



Lingolsheim collaborates with residents and local authorities to address community-related topics. The site also engages with the community on blood donation projects and breast cancer awareness initiatives.



Dessau's community programme supports Science, technology, engineering and mathematics (STEM) education initiatives in local schools, provides educational sessions on healthcare topics, promotes blood donation, and develops health programmes in collaboration with local healthcare institutions.



Supporting the local economy in Dessau

Octapharma is part of a cluster of pharmaceutical and biotechnology companies in the municipality of Dessau-Rosslau, Saxony-Anhalt, in Germany. We employ around 300 people at our packaging and logistics centre in the region, and we partner with many local businesses and suppliers.

Environmental stewardship and resilience

We minimise our footprint through climate action, water management, resource efficiency and safe chemical use while strengthening resilience.

Climate change

While we do contribute to climate change by emitting greenhouse gases (GHGs), we also see the need to respond to physical and transition risks and opportunities arising from it. Our climate action, therefore, involves both climate change mitigation and adaptation across our value chain.

We have set robust, science-based climate targets for the entire Octapharma Group that are aligned with the goal of the Paris Agreement to limit global warming to 1.5°C.

- Near-term target**
 - By **2035**, Octapharma aims to reduce absolute greenhouse gas emissions from its own operations and value chain (Scope 1, Scope 2 and Scope 3) by **63%** compared to the base year 2024.
- Long-term Net-Zero target**
 - By **2050**, Octapharma aims to reduce absolute greenhouse gas emissions from its own operations and value chain (Scope 1, Scope 2 and Scope 3) by **90%** compared to the base year 2024.

We have several climate action initiatives in place, including:



Replacement of traditional fluorinated refrigerants with alternative natural refrigerants that have a lower global warming potential.



Improving energy efficiency through upgrading machinery and HVAC systems, installing modern heat recovery systems and heat pumps, and optimising air exchange rates in cleanrooms.



Purchase of renewable energy and installation of photovoltaic (PV) systems to reduce our dependence on fossil fuels.



Optimising transport routes, requiring the use of biofuels in road transport where possible, and reviewing how we can use sea transport instead of air freight when delivering our products to customers.

Key Performance Indicators*

	2025	2024	2023
Energy consumption, MWh per tonne of plasma	23.52	23.73	26.14
CO₂e emissions, tonne per tonne of plasma	1.14	1.16	1.53

* The reported KPIs cover our production and R&D sites.

Water

The production of plasma-derived medicines requires large quantities of purified water, mainly for cleaning equipment and facilities. We are committed to using water responsibly.

We have targets to reduce both water use and wastewater at all production and packaging and logistics sites. At these sites we aim to:



Reduce water use in relation to the amount of plasma processed in production by 20% by 2027 compared with the 2022 baseline. This corresponds to reducing water withdrawal to less than 130 m³ per tonne of plasma in 2027.



Reduce wastewater by 30% in relation to the amount of plasma processed in production by 2027 compared with the 2022 baseline. This corresponds to reducing wastewater to less than 120 m³ per tonne of plasma in 2027.

In 2025, we achieved our interim water use target of 160 m³ per tonne of plasma processed. Wastewater volumes were slightly lower compared to previous years, at 120 m³ per tonne of plasma processed.

Through process optimisation and change of chemicals for pH neutralisation, we were also able to reduce contaminants in effluents.


Key Performance Indicators*

	2025	2024	2023
Wastewater consumption (kCbm/tonne of plasma)	0.12	0.12	0.13
Municipal water use (kCbm/tonne of plasma*)	0.15	0.15	0.16

* One kilocubic meter equals 1,000 cubic metres (1,000 m³).

Neutralising wastewater with CO₂

Our sites in Vienna and Springe have facilities that run flue gas from steam boilers through wastewater to neutralise effluents. This process involves capturing CO₂ from boiler fumes and using it to treat the chemical composition of the wastewater. This helps to both reduce the site's CO₂ emissions and mitigate the impact of chemical emissions on water systems.



[Explore Octapharma's commitment to environmental stewardship and resilience.](#)

Use of chemicals

Proper handling of chemicals is essential for safety, product quality and environmental protection. All production sites have local policies and standard operating procedures (SOPs) in place to guide the safe use of chemicals and prevent pollution.

We closely monitor our performance in the use and handling of chemicals to ensure our emissions are within regulatory limits, with all relevant data reported to the respective authorities.

Our project replacing Octoxynol-9, also known as Triton X100, proved sustainable without compromising effectiveness - paving the way for environmentally friendly changes in large-scale processes.

Resource use


Efficient resource management is key to minimising waste, optimising materials, and ensuring sustainable operations.

We use significant amounts of materials such as ethanol, nitrogen, laboratory consumables, protective clothing, filters, glass, plastics, cardboard and paper in the operation of plasma donation centres, and in the research, development, manufacturing and distribution of our products.

We are committed to optimising resource use and integrating circular economy principles in our operations to reduce waste and improve efficiency. All sites adhere to regulatory requirements for waste. These include the monitoring of treatment channels for recycling and reuse, and - for hazardous waste - for treatment and disposal.

Ethanol recycling

Our sites in Vienna, Lingolsheim and Stockholm already take a circular approach to the use of ethanol through regeneration, which enables around 80–85% of ethanol to be recycled. The process will be introduced at our Springe site in the coming years. The regeneration process involves recovering ethanol from an ethanol-water mixture at our ethanol distillation plants. Regenerated waste ethanol is then returned to our production sites.



[Explore Octapharma's commitment to environmental stewardship and resilience.](#)

Forward-looking statements disclaimer

This document may contain forward-looking statements, including statements regarding the company's objectives, intentions, expectations, plans and outlook in relation to non-financial matters. Such statements are based on current assumptions and information available at the time of preparation and reflect the company's present understanding and expectations.

Forward-looking statements are inherently subject to risks, uncertainties and factors beyond the company's control, which may cause actual outcomes, performance or developments to differ materially from those expressed or implied. These risks and uncertainties may relate, among other things, to regulatory developments, market conditions, environmental and social factors, and changes in applicable laws or reporting requirements.

Octapharma undertakes no obligation to update or revise any forward-looking statements, except as required by applicable European Union or national legislation. No assurance can be given that the expectations described in this document will be realised. Readers are cautioned not to place undue reliance on forward-looking statements.

Nothing in this document should be construed as a financial or profit forecast. This document is prepared for information purposes only and in accordance with applicable EU non-financial reporting requirements.

For further information on Octapharma's sustainability strategy, commitments and progress, please visit www.octapharma.com/sustainability

Publisher: Octapharma Nordic AB
Content: Octapharma Group Sustainability
Design: noGrey s.r.o.